Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesFulgent Genetics Inc

Fulgent Genetics Inc

Healthcare Diagnostics & Research
PortfolioPortfolio WatchlistWatchlist
Company price
23.74 USD 5.08 ( 27.22%)
Last update at 2026-11-06T21:18:00Z
VOLUME
943407
Market Cap
497.82M

Momentum Score

…

Fulgent Genetics, Inc. provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases. Its therapeutic development solutions focus on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform to enhance the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. The company operates picture genetics platform, which includes gene probes, data suppression and comparison algorithms, adaptive learning software, and proprietary laboratory information management systems that helps customers to identify health markers in their personal DNA. It serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, large corporations, and patients. Fulgent Genetics, Inc. was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. The company was founded in 2011 and is headquartered in El Monte, California.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
19.64
Low
23.84
High
52 Week Price Range
13.46
Low
31.04
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Fulgent Genetics runs a CLIA-certified lab offering high-throughput molecular and genomic testing for clinical, public-health and research clients. Long-term growth may come from broader adoption of genomic testing in oncology and rare disease, expanded test menus and scalable lab capacity that could support volume growth and precision-medicine demand.
Key risks include cyclicality from reduced COVID-19 testing, reimbursement and regulatory pressure, competition from larger diagnostics providers and execution risk in scaling new services.

Risk Score
Medium

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
18.66
Dividend Yield
-
Revenue TTM
322.67M
Revenue Per Share
10.48
Gross Profit TTM
130.88M
Debt / Equity
0.00
ROE
-5.51%
Net Debt
-49.72M
ROCE
-6.20%
Diluted EPS TTM
-1.97

Insight News

View All

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -70.03M -51.96M -174.09M 184.03M 677.30M
Minority interest 1.12M 1.11M 1.47M 1.48M 1.12M
Net income -60.51M -42.71M -167.82M 143.40M 507.36M
Selling general administrative 116.66M 88.11M 89.00M 111.07M 50.73M
Selling and marketing expenses 43.37M 36.25M 41.47M 38.92M 24.44M
Gross profit 130.88M 107.22M 104.46M 366.90M 777.05M
Reconciled depreciation 24.12M 24.93M 29.41M 32.66M 1.71M
Ebit -69.95M -73.92M -173.60M 178.53M 675.95M
Ebitda -45.83M -48.99M -147.45M 190.97M 677.66M
Depreciation and amortization 24.12M 24.93M 26.14M 12.45M 1.71M
Non operating income net other - - - - 5.08M
Operating income -91.10M -73.92M -195.53M 178.53M 675.95M
Other operating expenses 413.77M 357.39M 484.74M 437.47M 316.63M
Interest expense 0.07M 0.17M 0.49M 5.50M 6.21M
Tax provision -8.39M -8.14M 2.63M 42.10M 174.79M
Interest income 30.92M 31.47M 18.61M 5.50M 1.35M
Net interest income 30.84M 31.47M 18.61M 5.50M 1.35M
Income tax expense -8.39M -8.14M 1.15M 42.10M 174.79M
Total revenue 322.67M 283.47M 289.21M 618.97M 992.58M
Total operating expenses 221.97M 181.13M 299.99M 185.40M 101.10M
Cost of revenue 191.80M 176.25M 184.76M 252.07M 215.53M
Total other income expense net 21.07M 21.96M 21.44M 5.50M 1.35M
Net income from continuing ops -61.63M -43.82M -64.98M 141.92M 506.24M
Net income applicable to common shares - - - 143.40M 507.36M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 1213.53M 1219.96M 1273.11M 1386.05M 1278.72M
Intangible assets 64.79M 134.98M 143.05M 150.64M 35.91M
Other current assets 129.65M 10.05M 26.25M 22.25M -12.21M
Total liab 106.81M 90.81M 139.82M 116.18M 112.84M
Total stockholder equity 1111.99M 1133.23M 1136.10M 1269.88M 1165.88M
Other current liab -69.41M 22.84M 49.10M 58.35M 36.69M
Common stock 0.00M 0.00M 0.00M 0.00M 0.00M
Capital stock 0.00M 0.00M 0.00M 0.00M 0.00M
Retained earnings 529.95M 590.47M 633.17M 801.00M 657.60M
Other liab - - - 17.46M 0.79M
Good will 25.08M 22.05M 22.05M 143.03M 50.90M
Other assets - - 0.00M 26.56M 912.63M
Cash 50.19M 55.14M 97.47M 79.51M 164.89M
Total current liabilities 84.97M 72.90M 73.02M 116.18M 112.84M
Current deferred revenue 28.14M 29.84M 2.87M 14.09M 34.38M
Net debt -49.72M -46.68M -82.57M -58.87M -143.61M
Short term debt 0.48M 1.85M 5.68M 20.64M 21.28M
Short long term debt 0.48M 0.41M 1.18M 20.64M 21.28M
Short long term debt total 0.48M 8.47M 14.91M 20.64M 21.28M
Other stockholder equity 574.52M 543.13M 481.28M 477.39M 487.07M
Property plant equipment - - - 98.92M 62.29M
Total current assets 550.49M 353.57M 507.85M 905.63M 1074.46M
Long term investments 369.27M 570.35M 444.01M 339.03M 507.01M
Net tangible assets - - - 973.01M 1165.88M
Short term investments 285.88M 202.96M 326.68M 773.38M 770.65M
Net receivables 84.76M 77.03M 57.45M 52.75M 138.91M
Long term debt 1.96M 2.49M 2.96M - -
Inventory 10.60M 8.38M 5.83M 4.28M 12.21M
Accounts payable 18.65M 18.36M 15.36M 23.09M 20.49M
Noncontrolling interest in consolidated entity - - - - 7.13M
Accumulated other comprehensive income 7.51M -0.37M 1.21M -20.90M -0.76M
Common stock total equity - - - - 0.00M
Retained earnings total equity - - - - 657.60M
Non currrent assets other 460.62M 33.46M 32.03M -233.63M 141.97M
Non current assets total 663.03M 866.39M 765.26M 480.42M 204.26M
Capital lease obligations 5.24M 5.56M 11.10M - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 130.16M -58.35M 38.90M -261.31M -460.90M
Change to liabilities - - - -25.34M -12.21M
Total cashflows from investing activities 111.37M -58.35M 38.90M -261.31M -546.55M
Net borrowings -0.87M -1.77M -20.00M -1.07M -0.01M
Total cash from financing activities -14.79M -4.85M -47.78M -77.14M 85.41M
Change to operating activities - - - -40.47M 19.76M
Net income -61.63M -43.82M -175.24M 141.92M 506.24M
Change in cash -4.95M -42.19M 17.97M -85.39M 77.47M
Begin period cash flow 55.28M 97.47M 79.51M 164.89M 87.43M
End period cash flow 50.33M 55.28M 97.47M 79.51M 164.89M
Total cash from operating activities -101.64M 21.06M 27.00M 253.52M 538.58M
Issuance of capital stock - - 0.00M 0.00M 89.47M
Depreciation 24.12M 24.93M 26.14M 32.66M 11.00M
Other cashflows from investing activities 0.01M 0.31M 0.78M - -81.84M
Change to account receivables -23.25M -16.30M 2.39M 68.64M 42.30M
Sale purchase of stock -10.88M -3.12M -27.79M -74.34M 89.57M
Other cashflows from financing activities -3.04M 0.05M 0.00M -1.77M -4.06M
Change to netincome - - - 75.45M 22.89M
Capital expenditures 22.57M 40.31M 22.21M 18.77M 23.84M
Change receivables - - - - 42.30M
Cash flows other operating - - - - 4.45M
Cash and cash equivalents changes - - - - 77.43M
Change in working capital -117.63M -7.24M 2.84M 2.00M -2.68M
Stock based compensation 39.58M 44.48M 42.92M 32.64M 15.88M
Other non cash items 15.14M 7.86M 122.73M 43.46M 15.97M
Free cash flow -124.21M -19.25M 4.80M 234.75M 514.73M

Peer Comparison*

Sector: Healthcare Industry: Diagnostics & Research

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
FLGT
Fulgent Genetics Inc		 5.08
27.22%		 23.74 - 7.70 1.54 0.41 0.41 2.34
TMO
Thermo Fisher Scientific Inc		 17.82
2.63%		 694.76 34.71 23.87 4.62 4.43 5.29 20.89
DHR
Danaher Corporation		 3.91
1.73%		 230.25 29.09 28.01 5.67 3.20 6.00 19.09
WUXIF
WuXi AppTec Co. Ltd		 -
-%		 25.45 22.29 17.95 1.53 5.98 8.39 14.30
WUXAY
WuXi AppTec Co. Ltd		 -0.31
1.23%		 24.85 23.28 18.73 1.51 6.24 8.39 14.30

Profile*

Fulgent Genetics Inc

Fulgent Genetics, Inc. provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases. Its therapeutic development solutions focus on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform to enhance the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. The company operates picture genetics platform, which includes gene probes, data suppression and comparison algorithms, adaptive learning software, and proprietary laboratory information management systems that helps customers to identify health markers in their personal DNA. It serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, large corporations, and patients. Fulgent Genetics, Inc. was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. The company was founded in 2011 and is headquartered in El Monte, California.

4399 Santa Anita Avenue, El Monte, CA, United States, 91731

626 350 0537

https://www.fulgentgenetics.com

1315

Name Title Year Born
Mr. Ming Hsieh Chairman & CEO 1956
Mr. Jian Xie COO & Pres 1966
Mr. Paul Kim Chief Financial Officer 1967
Dr. Han Lin Gao D.A.B.M.G., F.A.C.M.G., FACMG, M.D., Ph.D. Chief Scientific Officer & Laboratory Director 1967
Ms. Natalie Prescott VP of Legal & Deputy Gen. Counsel NA
Ms. Doreen Ng VP of Operations & Compliance and GM of Houston Office NA
Mr. Jakub Sram VP of Bus. Devel. & Sales NA
Ms. Ellen Tsui VP of HR NA
Mr. Brandon Perthuis Chief Commercial Officer NA
Dr. Lawrence M. Weiss M.D. Chief Medical Officer 1957

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

ITH
CAD 2.15
+27.68%
HG
CAD 4.11
+19.13%
PPTA
CAD 27.74
+17.99%
UCU
CAD 2.10
+17.32%
GAU
CAD 3.49
+16.72%
TSU
CAD 29.67
-29.71%
PXT
CAD 19.73
-16.91%
LAS-A
CAD 230.50
-9.25%
IFP
CAD 13.50
-8.35%
NFI
CAD 24.01
-7.80%

Equity Sectors*

  • Basic Materials

    +3.74%

  • Communication Services

    +0.56%

  • Consumer Cyclical

    -0.34%

  • Consumer Defensive

    +0.11%

  • Energy

    +1.33%

  • Financial Services

    -0.26%

  • Healthcare

    +2.54%

  • Industrials

    -0.11%

  • Real Estate

    -0.23%

  • Technology

    +1.91%

  • Utilities

    +1.05%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…